Cosmo Pharmaceuticals (Group)

https://www.cosmopharmaceuticals.com

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected gastrointestinal disorders and endoscopic procedures. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD (inflammatory bowel disease), such as ulcerative colitis and Crohn’s disease, and colon infections. In addition, the company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer and has a large shareholding in Cassiopea SpA, a clinical-stage specialty pharmaceutical company focusing on developing and commercializing innovative and differentiated medical dermatology products. Cosmo’s MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Nogra and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate ulcerative colitis, licensed in the U.S. to Santarus/Salix/Valeant and in the rest of the world to Ferring. Cosmo’s proprietary MMX® technology is at the core of the company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (good manufacturing practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in colon. *

	Start	2005-05-01 existent
	Industry	gastrointestinal drug
	Industry 2	MMX Multi Matrix System™ drug delivery technology
	Person	Della Chà, Alessandro (Cosmo Pharmaceuticals 201507 CEO)
	Person 2	Donnelly, Niall (Cosmo Pharmaceuticals 201607 CFO)

	Region	Lainate (MI)
	Country	Italy
	Street	1 Via Cristoforo Colombo
	City	20020 Lainate (MI)
	Tel	+39-02-9333-7614
		Address record changed: 2020-12-02

Basic data	Employees	D: 101 to 500 (2016-12-31)
	Currency	EUR
	Annual sales	67,664,000 (revenue, total, consolidated (2016) 2016-12-31)
	Profit	19,340,000 (2016-12-31)
	Cash	117,649,000 (2016-12-31)

		* Document for »About Section«:

		Record changed: 2023-07-10